Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
The Delcath Systems Inc (DCTH) news page on Stock Titan aggregates company announcements, clinical updates, and financial disclosures for this interventional oncology business focused on primary and metastatic liver cancers. Delcath’s communications frequently highlight developments related to its proprietary hepatic delivery technologies, HEPZATO KIT and the CHEMOSAT Hepatic Delivery System for Melphalan, which are used in percutaneous hepatic perfusion (PHP) procedures.
Investors and observers can use this news feed to follow earnings reports and financial updates, including quarterly and preliminary revenue results, product revenue from HEPZATO KIT in the United States and CHEMOSAT in Europe, gross margin commentary, and discussions of non-GAAP measures such as adjusted EBITDA. The company also issues releases on capital allocation and corporate actions, such as authorization of share repurchase programs and equity inducement grants under stock incentive plans.
A significant portion of Delcath’s news flow centers on clinical and scientific developments. Recent announcements describe subgroup analyses from the Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in unresectable metastatic uveal melanoma, the Phase 2 CHOPIN trial evaluating CHEMOSAT with ipilimumab and nivolumab, real-world evidence from retrospective analyses of metastatic uveal melanoma patients, and a 10-year single-center experience with CHEMOSAT in liver-dominant disease. The company also highlights expert narrative reviews discussing PHP with melphalan using HEPZATO KIT, including patient selection, technique, and outcomes.
Additional updates include participation in investor conferences and scheduling of earnings calls, providing context for how Delcath communicates with the capital markets. For users tracking DCTH, this page offers a centralized view of regulatory, clinical, and financial news that shapes the company’s progress in liver-directed oncology therapies. Bookmark this feed to monitor new data releases, product-related publications, and ongoing disclosures from Delcath Systems Inc.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Delcath Systems (NASDAQ: DCTH) announced an amendment to its loan agreement with Avenue Venture Opportunities Fund, allowing for an interest-only period from March 31, 2023 to September 30, 2023. This defers approximately $4.3 million in principal payments. The company may extend this period to December 31, 2023 if it secures FDA approval for the HEPZATO Kit and raises at least $10 million through equity sales. Delcath will issue 34,025 warrants to Avenue with an exercise price of $0.01. This support aims to enhance the company's cash runway ahead of its PDUFA date on August 14, 2023.
Delcath Systems, Inc. (Nasdaq: DCTH) has completed a $25 million private placement with the potential for an additional $60 million based on milestone achievements. The financing, led by Vivo Capital and supported by various investors, is intended to fund operations through the anticipated FDA PDUFA date of August 14, 2023 for its product HEPZATO. The total proceeds are expected to cover working capital and general corporate purposes, with warrants providing further potential funding. The deal enables funding for commercialization if HEPZATO receives approval.
Delcath Systems, Inc. (DCTH) announced its fourth quarter and full year 2022 results, emphasizing significant milestones, including FDA acceptance of the NDA resubmission for Hepzato Kit® with a PDUFA date of August 14, 2023. The company secured $25 million in upfront financing, with potential additional funding of up to $60 million. Product revenue increased to $0.6 million in Q4 2022, up from $0.2 million in Q4 2021. However, Delcath reported a net loss of $8.5 million in Q4 2022, increasing its annual net loss to $36.5 million. As of December 31, 2022, cash holdings decreased to $11.8 million from $26.9 million the previous year.
Delcath Systems has secured $25 million in upfront financing, with potential additional funding of $60 million based on milestone achievements, totaling up to $85 million.
This capital will support the company through the anticipated PDUFA date of August 14, 2023 for HEPZATO approval and its commercialization efforts. Key investors include Vivo Capital and Logos Capital. The financing involves issuing Series F Convertible Preferred Stock and warrants, contingent on shareholder approval for conversions. Canaccord Genuity served as placement agent for this private placement.